Quick Answer
TG THERAPEUTICS, INC. reported Cash and Equivalents of $79.15 million for fiscal year 2025.
TG THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $79.15M | -56.0% |
| 2024 | $179.89M | +93.6% |
| 2023 | $92.93M | -9.2% |
| 2022 | $102.30M | -65.8% |
| 2021 | $298.89M | -46.0% |
| 2020 | $553.44M | +391.3% |
| 2019 | $112.64M | +168.5% |
| 2018 | $41.96M | -26.0% |
| 2017 | $56.72M | +126.6% |
| 2016 | $25.03M | -54.5% |
| 2015 | $55.06M | -1.2% |
| 2014 | $55.71M | +37.6% |
| 2013 | $40.49M | +146.0% |
| 2012 | $16.46M | +68.8% |
| 2011 | $9.75M | — |
| 2011 | $0.00 | — |
| 2010 | $0.00 | — |
| 2009 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.08M | -62.2% | -42.6% |
| June 30, 2025 | $129.13M | +55.7% | -2.3% |
| March 31, 2025 | $132.14M | +75.1% | -26.5% |
| December 31, 2024 | $179.89M | +93.6% | -8.1% |
| September 30, 2024 | $195.82M | +29.8% | +136.2% |
| June 30, 2024 | $82.91M | -14.5% | +9.8% |
| March 31, 2024 | $75.48M | +22.8% | -18.8% |
| December 31, 2023 | $92.93M | -9.2% | -38.4% |
- TG THERAPEUTICS, INC. showed a decrease of -56.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from TG THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: